ESR1 and breast carcinoma: In our study, we proposed the following drug resistance model: during paclitaxel therapy for breast cancer, paclitaxel can active ERα expression and then ERα can transcriptionally regulate the CD44 gene, which is responsible for resistance to chemotherapy agents.